Management of Respiratory Viral Infections in Hematopoietic Cell Transplant Recipients and Patients With Hematologic Malignancies
- 15 November 2014
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 59 (suppl_5), S344-S351
- https://doi.org/10.1093/cid/ciu623
Abstract
Despite preventive strategies and increased awareness, a high incidence of respiratory viral infections still occur in patients with hematologic malignancies (HMs) and in recipients of hematopoietic cell transplant (HCT). Progression of these viral infections to lower respiratory tract may prove fatal, especially in HCT recipients. Increasing evidence on the successful use of ribavirin (alone or in combination with immunomodulators) for the treatment of respiratory syncytial virus infections in HM patients and HCT recipients is available from retrospective studies; however, prospective clinical trials are necessary to establish its efficacy with confidence. The impact on progression to pneumonitis and/or mortality of treating parainfluenza virus infections with available (ribavirin) or investigational (DAS181) antiviral agents still needs to be determined. Influenza infections have been successfully treated with neuraminidase inhibitors (oseltamivir or zanamivir); however, the efficacy of these agents for influenza pneumonia has not been established, and immunocompromised patients are highly susceptible to emergence of antiviral drug resistance, most probably due to prolonged viral shedding. Infection control measures and an appreciation of the complications following respiratory viral infections in immunocompromised patients remain crucial for reducing transmission. Future studies should focus on strategies to identify patients at high risk for increased morbidity and mortality from these infections and to determine the efficacy of novel or available antiviral drugs.Keywords
This publication has 67 references indexed in Scilit:
- Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipientsCurrent Opinion in Infectious Diseases, 2011
- Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181Journal of Antimicrobial Chemotherapy, 2010
- A Recombinant Sialidase Fusion Protein Effectively Inhibits Human Parainfluenza Viral Infection In Vitro and In VivoThe Journal of Infectious Diseases, 2010
- A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virusProceedings of the National Academy of Sciences of the United States of America, 2010
- Laninamivir Prodrug CS-8958, a Long-Acting Neuraminidase Inhibitor, Shows Superior Anti-Influenza Virus Activity after a Single AdministrationAntimicrobial Agents and Chemotherapy, 2010
- DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysisJournal of Antimicrobial Chemotherapy, 2009
- Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global PerspectiveTransplantation and Cellular Therapy, 2009
- Triple Combination of Oseltamivir, Amantadine, and Ribavirin Displays Synergistic Activity against Multiple Influenza Virus Strains In VitroAntimicrobial Agents and Chemotherapy, 2009
- DAS181 Inhibits H5N1 Influenza Virus Infection of Human Lung TissuesAntimicrobial Agents and Chemotherapy, 2009
- The challenge of respiratory virus infections in hematopoietic cell transplant recipientsBritish Journal of Haematology, 2008